Novartis on Thursday posted a slightly more optimistic full-year earnings forecast, citing the strong growth of drugs such as ...

AbbVie ABBV has been expanding its oncology portfolio over the past few years. While the company was originally focused on two blood-cancer drugs — Imbruvica and Venclexta — it has since built a ...